Pfizer Moves Close to Deals Target With Seagen Buy, Lawyer Says

Pfizer Inc.‘s deal-making goal is close to complete with its planned acquisition of cancer-drug maker Seagen Inc., according to an attorney who worked on the tie-up.

Pfizer Chief Executive Officer Albert Bourla told analysts last year the company planned to add $25 billion in revenue through dealmaking by 2030. The Seagen acquisition announced March 13 moves the company $10 billion closer to that goal, according to Pfizer estimates.

“They’re 85% to 90% of the way to achieve that goal” of $25 billion, said David Lam, a corporate partner at Wachtell, Lipton, Rosen & Katz, which advised Pfizer on the ...